Rodriguez Javier sold 6,560 shares of BioXcel Therapeutics, Inc. at $1.08 for −$7.11k on May 20, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
See Remarks
See Remarks
Filed May 22, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$7,111.04Shares × reported price
Shares traded
6,560Common Stock
Price per share
$1.08Reported price. Read footnotes for ranges.
% of reported position traded
19.66%This security and ownership context
Holdings after
26,803Direct
Trade date
May 20, 2026Sell
Filed
May 22, 2026, 7:02 PM ET2-day reporting delay
Accession
0001104659-26-065839Code S · Transaction 384011
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 33,363 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
May 4, 2026Option exercise17,500$0.00$0Trade 384012
May 4, 2026Option exercise17,500——Trade 384010
3 transaction rows in this filing. Joint filers share the same rows.

BTAI price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
BTAI · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +6.2%1w ago +5.3%1d ago −4.4%
Returns since7d +3.5%30d +6.2%90d −29%180d1y

Footnotes in full

F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 3, 2026 solely to cover taxes due in connection with the vesting of restricted stock units. F3: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $1.07 to $1.09. The Reporting Person undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F4: On January 1, 2026, the Reporting Person was granted 70,000 RSUs, vesting as to 25% of the underlying shares on the six-month anniversary of the original promise date of November 4, 2025 (the "Vesting Commencement Date"), with the remaining 75% vesting in three equal installments of 25% on the last day of each subsequent six-month period thereafter, such that the RSUs are fully vested on the two-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.